InventisBio, a Shanghai company developing novel small molecule drugs, completed a $147 million series D financing led by GL Ventures, a Hillhouse affiliate. It has four drug candidates in various clinical stage trials, including two registration trials. The company develops molecules with best-in-class and first-in-class potential for unmet needs in cancer and metabolic diseases. Its products target HER2 positive breast cancer, non-small cell lung cancer, solid tumors, gout and NASH. More details.... Share this with colleagues: // //